Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Jerling

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Therapeutic Drug Monitoring|February 1, 1994
The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptylineM Jerling, L Bertilsson, F Sjöqvist
Journal of Clinical Psychopharmacology|October 1, 1995
Comments to "interaction between caffeine and clozapine"J A Carrillo, M Jerling, L Bertilsson
British Journal of Clinical Pharmacology|November 1, 1994
Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood methodM Jerling, Y Merlé, F Mentré, et al.
Therapeutic Drug Monitoring|August 1, 1994
Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring serviceM Jerling, L Lindström, U Bondesson, et al.
British Journal of Clinical Pharmacology|February 12, 1998
Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood methodM Jerling, Y Merlé, F Mentré, et al.
British Journal of Clinical Pharmacology|August 1, 1997
Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic doseU Hellgren, I Berggren-Palme, Y Bergqvist, et al.
European Journal of Clinical Pharmacology|January 1, 1996
Comparison between concentrations of racemic mefloquine, its separate enantiomers and the carboxylic acid metabolite in whole blood serum and plasmaU Hellgren, J Jastrebova, M Jerling, et al.
Psychiatric Genetics|June 13, 1998
Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophreniaE G Jönsson, M L Dahl, H K Roh, et al.
Clinical Pharmacology and Therapeutics|April 1, 1996
The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixolM Jerling, M L Dahl, A Aberg-Wistedt, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1987
Metabolic products of arachidonic acid in the central nervous system: possible role in mental disordersA A Mathé, B Apéria, P Bergman, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Therapeutic Drug Monitoring|February 1, 1994
The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptylineM Jerling, L Bertilsson, F Sjöqvist
Journal of Clinical Psychopharmacology|October 1, 1995
Comments to "interaction between caffeine and clozapine"J A Carrillo, M Jerling, L Bertilsson
British Journal of Clinical Pharmacology|November 1, 1994
Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood methodM Jerling, Y Merlé, F Mentré, et al.
Therapeutic Drug Monitoring|August 1, 1994
Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring serviceM Jerling, L Lindström, U Bondesson, et al.
British Journal of Clinical Pharmacology|February 12, 1998
Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood methodM Jerling, Y Merlé, F Mentré, et al.
British Journal of Clinical Pharmacology|August 1, 1997
Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic doseU Hellgren, I Berggren-Palme, Y Bergqvist, et al.
European Journal of Clinical Pharmacology|January 1, 1996
Comparison between concentrations of racemic mefloquine, its separate enantiomers and the carboxylic acid metabolite in whole blood serum and plasmaU Hellgren, J Jastrebova, M Jerling, et al.
Psychiatric Genetics|June 13, 1998
Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophreniaE G Jönsson, M L Dahl, H K Roh, et al.
Clinical Pharmacology and Therapeutics|April 1, 1996
The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixolM Jerling, M L Dahl, A Aberg-Wistedt, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1987
Metabolic products of arachidonic acid in the central nervous system: possible role in mental disordersA A Mathé, B Apéria, P Bergman, et al.
Pageof 3